Clinical Hematology International

Latest Articles

Mini Review

How to Make the Right Diagnosis in Neutropenia

Elena E. Solomou, Christina Salamaliki, Maria Lagadinou
In Press, Uncorrected Proof, Available Online: 26 February 2021
Isolated neutropenia without anemia or thrombocytopenia is a common clinical problem. The etiology of neutropenia may vary from transient bone marrow suppression, caused by self-limited viral illnesses, to previously undiagnosed congenital syndromes or serious systemic diseases. Consequently, determining...
Research Article

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma

Treen Carson Michael Morris, Mary B. Drake, Paul J. Kettle, Tracey McGuigan, Maeve Leahy, Michael O’Dwyer, Helen Enright, Tanya O’Shea, Rakesh Popat, Heather E. Oakervee, Kwee Yong, Jamie D. Cavenagh, David A. Cairns, Alberto Alvarez-Iglesias, Gordon Cook
In Press, Corrected Proof, Available Online: 8 February 2021
When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in relapsed or refractory patients by comparing the response...
Review Article

The Many Faces of Cytokine Release Syndrome-Related Coagulopathy

Jiasheng Wang, John Doran
In Press, Corrected Proof, Available Online: 28 January 2021
Cytokine release syndrome (CRS) has been increasingly recognized in various conditions including the coronavirus disease 2019 (COVID-19). It is not only associated with systemic inflammatory symptoms, but also hematological complications such as coagulopathy. CRS can affect various components of the...
Review Article

Machine Learning Applications in the Diagnosis of Benign and Malignant Hematological Diseases

Ibrahim N. Muhsen, David Shyr, Anthony D. Sung, Shahrukh K. Hashmi
In Press, Corrected Proof, Available Online: 21 December 2020
The use of machine learning (ML) and deep learning (DL) methods in hematology includes diagnostic, prognostic, and therapeutic applications. This increase is due to the improved access to ML and DL tools and the expansion of medical data. The utilization of ML remains limited in clinical practice, with...
Research Article

Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation

Sejal Morjaria, Allen W. Zhang, Sohn Kim, Jonathan U. Peled, Simone Becattini, Eric R. Littmann, Eric. G. Pamer, Michael C. Abt, Miguel-Angel Perales
Volume 2, Issue 4, December 2020, Pages 156-164
Background: Monocytes are an essential cellular component of the innate immune system that support the host’s effectiveness to combat a range of infectious pathogens. Hemopoietic cell transplantation (HCT) results in transient monocyte depletion, but the factors that regulate recovery of monocyte populations...
Review Article

CART Cell Toxicities: New Insight into Mechanisms and Management

Anas Zahid, Elizabeth L. Siegler, Saad S. Kenderian
Volume 2, Issue 4, December 2020, Pages 149-155
T cells genetically engineered with chimeric antigen receptors (CART) have become a potent class of cancer immunotherapeutics. Numerous clinical trials of CART cells have revealed remarkable remission rates in patients with relapsed or refractory hematologic malignancies. Despite recent clinical success,...

COVID-19 in Hematologic Malignancies: Big Challenges

Yongxian Hu, Linqin Wang, Qu Cui, Elaine Tan Su Yin, Hengwei Wu, Arnon Nagler, He Huang
Volume 2, Issue 4, December 2020, Pages 173-175
Research Article

Emicizumab Associated Rhabdomyolysis in Hemophilia A

Joseph A. Wilson, Stephanie Hayden, Alexander Asamoah, Vivek R. Sharma, David C. Jennings, Ashok B. Raj
Volume 2, Issue 4, December 2020, Pages 165-167
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscle...

The Incidence and Timing of Blood Cultures in Multiple Myeloma – Results from a Retrospective, Single Center, Real-World Study

Agoston Gyula Szabo, Katrine Fladeland Iversen, Flemming Schønning Rosenvinge, Sören Möller, Torben Plesner
Volume 2, Issue 4, December 2020, Pages 168-172
Review Article

What’s Important and New in Hemochromatosis?

Pierre Brissot, Eolia Brissot
Volume 2, Issue 4, December 2020, Pages 143-148
Major advances in the understanding of genetic iron overload have led to a clarification of the nosology and terminology of the related diseases. The term hemochromatosis should be reserved to the entities where iron overload is related to hepcidin deficiency or hepcidin resistance. The diagnosis of...

B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Meghali Goswami, Katherine E. Lindblad, Rahul Ramraj, Pradeep K. Dagur, Julie Thompson, J. Philip McCoy, Christopher S. Hourigan
Volume 2, Issue 3, September 2020, Pages 125-128

Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation

Federica Ricci, Serena Balducci, Francesca Guerrini, Susanna Grassi, Elena Ciabatti, Claudia Baratè, Maria Immacolata Ferreri, Cecilia Giuliani, Angelo Valetto, Mario Petrini, Sara Galimberti
Volume 2, Issue 3, September 2020, Pages 129-131
Review Article

Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?

Anna Suska, David H. Vesole, Jorge J. Castillo, Shaji K. Kumar, Hari Parameswaran, Maria V. Mateos, Thierry Facon, Alessandro Gozzetti, Gabor Mikala, Marta Szostek, Joseph Mikhael, Roman Hajek, Evangelos Terpos, Artur Jurczyszyn
Volume 2, Issue 4, December 2020, Pages 133-142
Plasma cell leukemia (PCL) is an aggressive hematological malignancy characterized by an uncontrolled clonal proliferation of plasma cells (PCs) in the bone marrow and peripheral blood. PCL has been defined by an absolute number of circulating PCs exceeding 2.0 × 109/L and/or >20% PCs in the total...
Review Article

Cold Agglutinin Disease

Amy P. Gabbard, Garrett S. Booth
Volume 2, Issue 3, September 2020, Pages 95-100
Cold agglutinin disease (CAD) is an uncommon form of cold autoimmune hemolytic anemia (AIHA). It should be considered in the differential diagnosis of elderly patients with unexplained chronic anemia presenting with or without cold-induced symptoms in the extremities, such as the fingers, ears, and nose....
Research Article

Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors

Natasha A. Jain, Marcus Y. Chen, Sujata Shanbhag, Prathima Anandi, Xin Tian, Sawa Ito, Priyanka A. Pophali, Kimberly Doucette, Robert Q. Le, Upneet Chawla, Eleftheria Koklanaris, Richard W. Childs, A. John Barrett, Minoo Battiwalla
Volume 2, Issue 3, September 2020, Pages 109-116
Long-term allogeneic hematopoietic cell transplant (allo-HCT) survivors suffer an elevated risk of coronary heart disease (CHD). We conducted a prospective, nonrandomized, cross-sectional study to screen asymptomatic survivors at a single allo-HCT center using cardiac computed tomography (CT) involving...
Review Article

Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)

Uttam K. Rao, Brian G. Engelhardt
Volume 2, Issue 3, September 2020, Pages 101-108
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is...
Review Article

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Sarah A. Bird, Graham H. Jackson, Charlotte Pawlyn
Volume 2, Issue 2, June 2020, Pages 59-68
Multiple myeloma, the second most common hematological malignancy worldwide, has demonstrated dramatic improvements in outcome in the last decade. In newly diagnosed patients, induction chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care. After ASCT, the majority...
Research Article

Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation

Raheel Iftikhar, Qamar un Nisa Chaudhry, Tariq Mehmood Satti, Syed Kamran Mahmood, Tariq Ghafoor, Ghassan Umair Shamshad, Nighat Shahbaz, Mehreen Ali Khan, Tariq Azam Khattak, Jahanzeb Rehman, Muhammad Farhan, Saima Humayun, Humera Haq, Syeda Ammaara Anwaar Naqvi, Faiz Anwer, Humayoon Shafique Satti, Parvez Ahmed
Volume 2, Issue 2, June 2020, Pages 82-91
Allogeneic stem cell transplant for high-risk aplastic anemia (AA) yields inferior results using conventional cyclophosphamide (CY)-based conditioning. The use of fludarabine (Flu)-based regimens has resulted in improved outcomes in high-risk patients. Limited data are available comparing these two conditioning...
Research Article

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features

Bhagirathbhai Dholaria, Yenny Alejandra Moreno Vanegas, Nancy Diehl, Aaron C. Spaulding, Sue Visscher, Han W. Tun, Sikander Ailawadhi, Prakash Vishnu
Volume 2, Issue 3, September 2020, Pages 117-124
Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-risk DLBCL who received frontline rituximab, cycophosphamide,...
Review Article

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant

Samuel Cytryn, Maher Abdul-Hay
Volume 2, Issue 2, June 2020, Pages 49-58
Allogeneic hematopoietic cell transplant (Allo-HCT) is a potentially curative therapy for many malignant and nonmalignant hematological diseases. However, a suitable human leukocyte antigens (HLAs)-matched donor may not be available when the patient is in urgent need of a stem cell transplant. This challenge...
Review Article

The Evolving Landscape of Myelodysplastic Syndrome Prognostication

Jacob Shreve, Aziz Nazha
Volume 2, Issue 2, June 2020, Pages 43-48
Myelodysplastic syndromes (MDSs) are potentially devastating monoclonal deviations of hematopoiesis that lead to bone marrow dysplasia and variable cytopenias. Predicting severity of disease progression and likelihood to undergo acute myeloid leukemia transformation is the basis of treatment strategy....
Research Article

The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

M. Remberger, B. Grønvold, M. Ali, J. Mattsson, T. Egeland, K. U. Lundin, A. Myhre, I. Abrahamsen, D. Heldal, I. Dybedal, G. E. Tjønnfjord, T. Gedde-Dahl, Y. Fløisand
Volume 2, Issue 2, June 2020, Pages 74-81
The effect of CD34+ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological...
Research Article

Repeat Endoscopy Affects Patient Management in Gastrointestinal Graft-Versus-Host Disease

Ehsan Shabbir, Umar Farooq, Burhan Yanes, Margarida Magalhaes-Silverman
Volume 2, Issue 2, June 2020, Pages 69-73
Graft versus host disease (GVHD) of the gut is associated with significant morbidity and mortality after allogeneic hematopoietic cell transplant (allo-HCT). No guidelines exist regarding repeat endoscopy after failure of first-line treatment with steroids. We aimed to study if repeat endoscopic biopsy...